Patients’ experiences with GLP1-RAs – a systematic review
Sign Up to like & getrecommendations! Published in 2025 at "Scandinavian Journal of Primary Health Care"
DOI: 10.1080/02813432.2025.2477141
Abstract: Abstract Background Obesity is a complex condition and a recognized public health challenge. Previous treatment options were associated with high failure rates, but recent trials have shown that significant weight loss can be achieved with… read more here.
Keywords: experiences glp1; weight loss; systematic review; glp1 ras ... See more keywords
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism
Sign Up to like & getrecommendations! Published in 2021 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2021.1970744
Abstract: ABSTRACT Introduction A number of anti-diabetic treatments have been favored during the continuing spread of the current SARS-CoV-2 pandemic. Glucagon like peptide-1 receptor agonists (GLP1-RAs) are a group of antidiabetic drugs, the glucose reducing effect… read more here.
Keywords: hypothetical molecular; glp1 ras; receptor agonists; molecular mechanism ... See more keywords
Abstract 4118762: Large-scale multinational trends in the use of cardioprotective antihyperglycemic agents as first-line therapy in patients with type 2 diabetes and cardiovascular disease: a LEGEND-T2DM study
Sign Up to like & getrecommendations! Published in 2024 at "Circulation"
DOI: 10.1161/circ.150.suppl_1.4118762
Abstract: Background: US guidelines for type 2 diabetes (T2DM) recommend metformin as first-line anti-hyperglycemic therapy (AHT), but prioritizing the use of AHTs that reduce cardiovascular disease (CVD) risk – GLP1-RAs and SGLT2is – is increasingly suggested… read more here.
Keywords: ras sglt2is; use; type diabetes; glp1 ras ... See more keywords
641-P: Novel Microsphere Formulation Developments of Long-Acting GLP-1 RA Including Exenatide, Liraglutide, and Semaglutide
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-641-p
Abstract: Objective: Clinical applications of Glucagon-like peptide-1 receptor agonists (GLP1-RA) were greatly limited due to its short half-life. The current study aims at the formulation and characterization of sustained-release (SR)-GLP1-RAs to prolong the release profile with… read more here.
Keywords: lag phase; long acting; liraglutide semaglutide; formulation ... See more keywords
Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2022 at "Australian journal of general practice"
DOI: 10.31128/ajgp-07-21-6057
Abstract: BACKGROUND Type 2 diabetes (T2D) is a national health priority. Its rising prevalence is accompanied by a high burden of diabetes-related complications, many of which are preventable. Numerous glucose-lowering medications have been developed in recent years with growing… read more here.
Keywords: glp1 ras; glp1; glucagon like; peptide receptor ... See more keywords
Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms251910795
Abstract: The introduction of the term “Metabolic Steatotic Liver Disease” (MASLD) underscores the critical role of metabolic dysfunction in the development and progression of chronic liver disease and emphasizes the need for strategies that address both… read more here.
Keywords: fgf21 fetuin; glp1 ras; ras fgf21; crosstalk ... See more keywords